Patents by Inventor Patrice Debre

Patrice Debre has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250012799
    Abstract: The present disclosure relates to a HR1-derived polypeptide comprising 10 or more consecutive amino acids of the polypeptide of SEQ ID NO. 8 as disclosed in the description, or a polypeptide derivative thereof. This disclosure also concerns an immunogenic composition comprising a HR1-derived polypeptide as described herein. It also relates to an immunogenic composition comprising a nucleic acid encoding a HR1-derived polypeptide as described herein. In some preferred embodiments, the said nucleic acid consists of a ribonucleic acid.
    Type: Application
    Filed: April 7, 2022
    Publication date: January 9, 2025
    Inventors: Patrice DEBRE, Vincent VEILLARD, Christian PRADEYROL
  • Patent number: 10174080
    Abstract: The present invention relates to an immunogenic composition comprising an antigenic peptide of formula (I) below: Nt-S-X1-X2-X3-K-X4-Ct (I) [SEQ ID No 1], wherein Nt consists of a peptide having from 0 to 50 amino acids in length, Ct consists of a peptide having from 0 to 50 amino acids in length, each of X1 to X4 consists of an amino acid residue, wherein: (i) X1 means the specific amino acid W or (ii) X1 means any amino acid residue excepted W, (i) X2 means the specific amino acid S or (ii) X2 means any amino acid residue excepted S, (i) X3 means the specific amino acid N or (ii) X3 means any amino acid residue excepted N, (i) X4 means the specific amino acid S or (ii) X4 means any amino acid residue excepted S, with the proviso that three out of the four amino acid residues X1, X2, X3 and X4 mean the specific amino acid defined in their respective meaning (i) above, and the remaining amino acid residue among X1 to X4 means any amino acid residue excepted the specific amino acid residue defined in its meani
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: January 8, 2019
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), INNAVIRVAX
    Inventors: Patrice Debre, Vincent Vieillard
  • Publication number: 20180057535
    Abstract: The present invention relates to an immunogenic composition comprising an antigenic peptide of formula (I) below: Nt-S-X1-X2-X3-K-X4-Ct (I) [SEQ ID N° 1], wherein Nt consists of a peptide having from 0 to 50 amino acids in length, Ct consists of a peptide having from 0 to 50 amino acids in length, each of X1 to X4 consists of an amino acid residue, wherein: (i) X1 means the specific amino acid W or (ii) X1 means any amino acid residue excepted W, (i) X2 means the specific amino acid S or (ii) X2 means any amino acid residue excepted S, (i) X3 means the specific amino acid N or (ii) X3 means any amino acid residue excepted N, (i) X4 means the specific amino acid S or (ii) X4 means any amino acid residue excepted S, with the proviso that three out of the four amino acid residues X1, X2, X3 and X4 mean the specific amino acid defined in their respective meaning (i) above, and the remaining amino acid residue among X1 to X4 means any amino acid residue excepted the specific amino acid residue defined in its meani
    Type: Application
    Filed: September 22, 2017
    Publication date: March 1, 2018
    Applicants: Institut National de la Sante et de la Recherche Medicale (INSERM), INNAVIRVAX
    Inventors: Patrice DEBRE, Vincent VIEILLARD
  • Patent number: 9802983
    Abstract: The present invention relates to an immunogenic composition comprising an antigenic peptide of formula (I) below: Nt-S-X1-X2-X3-K-X4-Ct (I) [SEQ ID No 1], wherein —Nt consists of a peptide having from 0 to 50 amino acids in length, —Ct consists of a peptide having from 0 to 50 amino acids in length, —each of X1 to X4 consists of an amino acid residue, wherein: —(i) X1 means the specific amino acid W or (ii) X1 means any amino acid residue excepted W, —(i) X2 means the specific amino acid S or (ii) X2 means any amino acid residue excepted S, —(i) X3 means the specific amino acid N or (ii) X3 means any amino acid residue excepted N, —(i) X4 means the specific amino acid S or (ii) X4 means any amino acid residue excepted S, with the proviso that —three out of the four amino acid residues X1, X2, X3 and X4 mean the specific amino acid defined in their respective meaning (i) above, and —the remaining amino acid residue among X1 to X4 means any amino acid residue excepted the specific amino acid residue defined in
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: October 31, 2017
    Assignees: INSTITUT NATIONAL DE LA SANTÉET DE LA RECHERCHE MEDICALÉ (INSERM), INNAVIRVAX
    Inventors: Patrice Debre, Vincent Vieillard
  • Publication number: 20170128564
    Abstract: The present invention relates to the field of the in vitro diagnosis of the progression status of an infection of an individual with a virus belonging to the family of the Human Immunodeficiency Viruses (HIV) as well as with the therapeutical treatment of this infectious disease. The invention also relates to immunological compounds and vaccine compositions comprising a polypeptide derived from gp41.
    Type: Application
    Filed: November 23, 2016
    Publication date: May 11, 2017
    Inventors: Vincent VIEILLARD, Patrice DEBRE
  • Publication number: 20160031943
    Abstract: The present invention relates to an immunogenic composition comprising an antigenic peptide of formula (I) below: Nt-S-X1-X2-X3-K-X4-Ct (I) [SEQ ID No 1], wherein —Nt consists of a peptide having from 0 to 50 amino acids in length, —Ct consists of a peptide having from 0 to 50 amino acids in length, —each of X1 to X4 consists of an amino acid residue, wherein: —(i) X1 means the specific amino acid W or (ii) X1 means any amino acid residue excepted W, —(i) X2 means the specific amino acid S or (ii) X2 means any amino acid residue excepted S, —(i) X3 means the specific amino acid N or (ii) X3 means any amino acid residue excepted N, —(i) X4 means the specific amino acid S or (ii) X4 means any amino acid residue excepted S, with the proviso that —three out of the four amino acid residues X1, X2, X3 and X4 mean the specific amino acid defined in their respective meaning (i) above, and —the remaining amino acid residue among X1 to X4 means any amino acid residue excepted the specific amino acid residue defined in
    Type: Application
    Filed: September 30, 2015
    Publication date: February 4, 2016
    Applicants: Institut National de la Sante et de la Recherche Medicale (INSERM), INNAVIRVAX
    Inventors: Patrice DEBRE, Vincent VIEILLARD
  • Patent number: 9181299
    Abstract: The present invention relates to an immunogenic composition comprising an antigenic peptide of formula (I) below: Nt-S-X1-X2-X3-K-X4-Ct (I) [SEQ ID No 1], wherein—Nt consists of a peptide having from 0 to 50 amino acids in length, —Ct consists of a peptide having from 0 to 50 amino acids in length, —each of X1 to X4 consists of an amino acid residue, wherein: —(i) X1 means the specific amino acid W or (ii) X1 means any amino acid residue excepted W, —(i) X2 means the specific amino acid S or (ii) X2 means any amino acid residue excepted S, —(i) X3 means the specific amino acid N or (ii) X3 means any amino acid residue excepted N, —(i) X4 means the specific amino acid S or (ii) X4 means any amino acid residue excepted S, with the proviso that—three out of the four amino acid residues X1, X2, X3 and X4 mean the specific amino acid defined in their respective meaning (i) above, and—the remaining amino acid residue among X1 to X4 means any amino acid residue excepted the specific amino acid residue defined in its
    Type: Grant
    Filed: April 13, 2012
    Date of Patent: November 10, 2015
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Innavirvax
    Inventors: Patrice Debre, Vincent Vieillard
  • Publication number: 20140335119
    Abstract: The present invention relates to the field of the in vitro diagnosis of the progression status of an infection of an individual with a virus belonging to the family of the Human Immunodeficiency Viruses (HIV) as well as with the therapeutical treatment of this infectious disease. The invention also relates to immunological compounds and vaccine compositions comprising a polypeptide derived from gp41.
    Type: Application
    Filed: May 23, 2014
    Publication date: November 13, 2014
    Applicants: Institut National de la Sante et de la Recherche Medicale (INSERM), Assistance Publique Hopitaux de Paris
    Inventors: Vincent VIEILLARD, Patrice DEBRE
  • Publication number: 20140037666
    Abstract: The present invention relates to an immunogenic composition comprising an antigenic peptide of formula (I) below: Nt-S—X1-X2-X3-K—X4-Ct (I) [SEQ ID No 1], wherein—Nt consists of a peptide having from 0 to 50 amino acids in length, —Ct consists of a peptide having from 0 to 50 amino acids in length, —each of X1 to X4 consists of an amino acid residue, wherein: —(i) X1 means the specific amino acid W or (ii) X1 means any amino acid residue excepted W, —(i) X2 means the specific amino acid S or (ii) X2 means any amino acid residue excepted S, —(i) X3 means the specific amino acid N or (ii) X3 means any amino acid residue excepted N, —(i) X4 means the specific amino acid S or (ii) X4 means any amino acid residue excepted S, with the proviso that—three out of the four amino acid residues X1, X2, X3 and X4 mean the specific amino acid defined in their respective meaning (i) above, and—the remaining amino acid residue among X1 to X4 means any amino acid residue excepted the specific amino acid residue defined in its
    Type: Application
    Filed: April 13, 2012
    Publication date: February 6, 2014
    Applicant: INNAVIRVAX
    Inventors: Patrice Debre, Vincent Vieillard
  • Publication number: 20140024018
    Abstract: An in vitro method for the prognosis of progression of an HIV-1 infection in a patient infected with an HIV-1 virus, comprising the steps of: a) measuring the level of antibodies directed against the 3S peptide of SEQ ID NO 2 in a sample collected from the said patient, b) comparing the level of anti-3S antibodies measured at step a) with a reference value of anti-3S antibody level that is indicative of the progression of the HIV-1 infection.
    Type: Application
    Filed: February 21, 2012
    Publication date: January 23, 2014
    Applicants: INNAVIRVAX, Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Laurence Meyer, Vincent Viellard, Patrice Debre, Joël Crouzet
  • Patent number: 8372955
    Abstract: The present invention relates to the field of the in vitro diagnosis of the progression status of an infection of an individual with a virus belonging to the family of the Human Immunodeficiency Viruses (HIV) as well as with the therapeutical treatment of this infectious disease.
    Type: Grant
    Filed: October 29, 2007
    Date of Patent: February 12, 2013
    Assignees: Assistance Publique Hopitaux de Paris, Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Vincent Viellard, Patrice Debre
  • Patent number: 7915221
    Abstract: The present invention provides a method for the design and/or the selection of agonist or antagonist chemokine variants combining a phage display technology and a screening on living cells expressing the receptor of the corresponding native chemokine. It also provides RANTES variants having agonist properties towards said receptor, and methods for preventing and/or curing viral diseases, as well as clues for preventing and/or curing inflammatory or malignant diseases.
    Type: Grant
    Filed: April 2, 2007
    Date of Patent: March 29, 2011
    Assignee: Universite Pierre et Marie Curie (Paris VI)
    Inventors: Guy Gorochov, Oliver Hartley, Karim Dorgham, Patrice Debre, Robin Offord
  • Publication number: 20090136533
    Abstract: The present invention relates to the field of the in vitro diagnosis of the progression status of an infection of an individual with a virus belonging to the family of the Human Immunodeficiency Viruses (HIV) as well as with the therapeutical treatment of this infectious disease. The invention also relates to immunological compounds and vaccine compositions comprising a polypeptide derived from gp41.
    Type: Application
    Filed: January 29, 2009
    Publication date: May 28, 2009
    Applicants: INSERM (Institut National de la Recherche Medicale), Assistance Publique Hopitaux de Paris
    Inventors: Vincent Vieillard, Patrice Debre
  • Publication number: 20090117110
    Abstract: The present invention relates to the field of the in vitro diagnosis of the progression status of an infection of an individual with a virus belonging to the family of the Human Immunodeficiency Viruses (HIV) as well as with the therapeutical treatment of this infectious disease.
    Type: Application
    Filed: October 29, 2007
    Publication date: May 7, 2009
    Applicants: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE ( INSERM), ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
    Inventors: Vincent Vieillard, Patrice Debre
  • Publication number: 20090075874
    Abstract: The present invention provides a method for the design and/or the selection of agonist or antagonist chemokine variants combining a phage display technology and a screening on living cells expressing the receptor of the corresponding native chemokine. It also provides RANTES variants having agonist properties towards said receptor, and methods for preventing and/or curing viral diseases, as well as clues for preventing and/or curing inflammatory or malignant diseases.
    Type: Application
    Filed: April 2, 2007
    Publication date: March 19, 2009
    Inventors: Guy Gorochov, Oliver Hartley, Karim Dorgham, Patrice Debre, Robin Offord
  • Patent number: 7211564
    Abstract: The present invention provides a method for the design and/or the selection of agonist or antagonist chemokine variants combining a phage display technology and a screening on living cells expressing the receptor of the corresponding native chemokine. It also provides RANTES variants having agonist properties towards said receptor, and methods for preventing and/or curing viral diseases, as well as clues for preventing and/or curing inflammatory or malignant diseases.
    Type: Grant
    Filed: March 4, 2004
    Date of Patent: May 1, 2007
    Assignees: Universite Pierre et Marie Curie (ParisVI), Universite De Geneve
    Inventors: Guy Gorochov, Oliver Hartley, Karim Dorgham, Patrice Debre, Robin Offord
  • Publication number: 20070092525
    Abstract: The present invention relates to the field of the in vitro diagnosis of the progression status of an infection of an individual with a virus belonging to the family of the Human Immunodeficiency Viruses (HIV) as well as with the therapeutical treatment of this infectious disease. The invention also relates to immunological compounds and vaccine compositions comprising a polypeptide derived from gp41.
    Type: Application
    Filed: February 7, 2005
    Publication date: April 26, 2007
    Applicants: Institut National de la Sante et de la Recherche Medicale (INSERM), Assistance Publique Hopitaux de Paris
    Inventors: Vincent Vieillard, Patrice Debre
  • Publication number: 20060257318
    Abstract: The present invention relates to the field of the in vitro diagnosis nosis of the progression status of an infection of an individual with a virus belonging to the family of the Human Immunodeficiency Viruses (HIV) as well as with the therapeutical treatment of this infectious disease.
    Type: Application
    Filed: February 6, 2004
    Publication date: November 16, 2006
    Applicants: Institut National de la Sante et de la Recherche M, Assistance Publique Hopitaux de Paris
    Inventors: Vincent Vieillard, Patrice Debre
  • Publication number: 20050074463
    Abstract: The invention concerns treatment of infectious and tumoral pathologies comprising a anti-infective and/or anti-tumoral chemotherapeutic treatment phase inducing resistance mutations and a therapeutic vaccination phase directed against said resistance mutations and the agents used in said treatment More particularly, the invention concerns peptides of 8 to 80 amino acids of the HIV reverse transcriptase sequence and comprising at least a mutation with respect to said wild sequence of said enzyme, mutation induced in response to treatments by nucleoside and non-nucleoside analogues of the HIV reverse transcriptase. The invention also concerns a pharmaceutical composition or vaccine based on said peptides, for inducing an immune response specific of said mutated sequences and for enhancing or prolonging the efficiency of treatments with nucleoside or non-nucleoside analogues of the HIV reverse transcriptase.
    Type: Application
    Filed: September 14, 2001
    Publication date: April 7, 2005
    Applicant: Universite Pierre et Marie Curie-paris VI
    Inventors: Brigitte Autran, Assia Samri, Patrice Debre, Vincent Calvez, Christine Katlama, Gaby Haas
  • Publication number: 20040258659
    Abstract: The present invention provides a method for the design and/or the selection of agonist or antagonist chemokine variants combining a phage display technology and a screening on living cells expressing the receptor of the corresponding native chemokine. It also provides RANTES variants having agonist properties towards said receptor, and methods for preventing and/or curing viral diseases, as well as clues for preventing and/or curing inflammatory or malignant diseases.
    Type: Application
    Filed: March 4, 2004
    Publication date: December 23, 2004
    Inventors: Guy Gorochov, Oliver Hartley, Karim Dorgham, Patrice Debre, Robin Offord